However, our study contrasts with previous studies demonstrating that the delta between tests is associated with faster deterioration.18,19 To our knowledge, ours is the largest study of repeat PlGF-based testing, and we have demonstrated flat longitudinal biomarker profiles in women with an initial abnormal sFlt-1/PlGF ratio who were diagnosed with preeclampsia or who developed severe adverse outcomes. This evidence concerns the gene PGF and preeclampsia.